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Background: Sarcopenia, defined as skeletal muscle loss, has been known as a poor
prognosis factor in various malignant diseases The aim of this study is to investigate
the effect of sarcopenia on prognosis in patients with esophageal cancer who received
concurrent chemo- and radiotherapy (CCRT).
Methods: We retrospectively collected clinical data of 287 patients with esophageal
cancer who were treated by definite CCRT at Gangnam Severance and Severance
hospital from August 2005 to December 2014. The cross-sectional area of muscle at the
level of the third lumbar vertebra was measured using pre- and post-CCRT computed
tomography images. Sarcopenia was defined as skeletal muscle index <49 cm2/m2 for
men and of <31 cm2/m2 for women by Korean-specific cutoffs. Overall survival (OS) and
progression free survival (PFS) were analyzed according to sarcopenia.
Results: Sarcopenia identified before CCRT did not affect OS and PFS. However,
patients with post-CCRT sarcopenia showed shorter OS and PFS than patients without
it (median OS: 73 months vs. 28 months; median PFS: 34 months vs. 25 months,
respectively). Post-CCRT sarcopenia was an independent prognostic factor of poor OS
(hazards ratio: 1.697; 95% confidence interval: 1.036–2.780; P = 0.036). In multivariate
analysis, male sex (P = 0.004) and presence of CCRT-related complications, such
as esophagitis or general weakness were significantly associated with post-CCRT
sarcopenia (P = 0.016).
Conclusions: Sarcopenia after CCRT can be a useful predictor for long-term prognosis
in patients with esophageal cancer. To control CCRT-related complications may be
important to prevent skeletal muscle loss during CCRT.
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INTRODUCTION
Esophageal cancer is widely known as fatal and aggressive disease
(1). In the past, surgical treatment was the standard treatment for
esophageal cancer. Because of the poor prognosis after surgery,
a multidisciplinary approach is being made for the treatment of
esophageal cancer (2, 3). Concurrent chemo- and radiotherapy
(CCRT) is not only a treatment option for inoperable esophageal
cancer, but also is known as prefer approach for locally advanced
esophageal cancer (4, 5).
The patients with esophageal cancer mostly suffer from
dysphagia and poor oral intake, and it makes deleterious effects
to treatment compliance and outcomes. Therefore, it is necessary
for patients with esophageal cancer to help prevent malnutrition
through adequate nutritional support (6). Sarcopenia is a
condition characterized by loss of muscle mass and strength,
and critically associated with numerous clinical conditions such
as malnutrition, endocrine disease, inflammatory disease, and
malignancy (7, 8). It was originally described in the elderly
people, but now usually recognized in cancer patients. The
decrease in muscle mass is not always correlated with changes
in body weight, so it is not always the same as the decrease
in body mass index (BMI). Recent studies suggest that changes
in nutritional status and body composition are associated with
prognosis in cancer patients (9–12).
To assess muscle mass, various measurement methods are
used. Among them, computed tomography (CT) scan showed
superiority in accuracy and precision for evaluating muscle and
fat mass (13). Several studies have revealed the relationship
between preoperative sarcopenia and prognosis in patients with
esophageal cancer (14–17).
However, in our best knowledge, there is no study of the
relationship between sarcopenia and prognosis in esophageal
cancer patients who received definite CCRT. Therefore, we aimed
to investigate the changes in body composition before and after
FIGURE 1 | Axial computed tomography image of the third lumbar vertebra
used for the assessment of skeletal muscle area (highlighted in pink).
TABLE 1 | Baseline characteristics of patients and tumors.
Characteristics All
(n = 198)
Age (years, median [range]) 67 (36–91)
Sex
Male 190 (96.0)
Female 8 (4.0)
ECOG performance status
0–1 190 (96.0)
2–3 8 (4.0)
BMI (kg/m2, median [range]) 22.6 (15.1–33.3)
Hemoglobin (g/dL, median [range]) 13.6 (8.2–17.6)
Albumin (g/dL, median [range]) 4.2 (2.7–5.1)
Neutrophil / lymphocyte ratio 2.3 (0.9–44.8)
Esophageal stent insertion
No 152 (76.8)
Yes 46 (23.2)
Tumor location
Cervical 13 (6.6)
Upper thoracic 42 (21.2)
Mid thoracic 109 (55.1)
Lower thoracic 34 (17.2)
Tumor histology
Squamous cell carcinoma 195 (98.5)
Adenocarcinoma 3 (1.5)
Tumor differentiation
Well differentiation 25 (12.6)
Moderate differentiation 113 (57.1)
Poorly differentiation 41 (20.7)
Gx 19 (9.6)
Clinical tumor stage
T1 34 (17.2)
T2 31 (15.7)
T3 103 (52.0)
T4 30 (15.2)
Clinical nodal stage
N0 51 (25.8)
N1 107 (54.0)
N2 22 (11.1)
N3 18 (9.1)
Chemotherapy regimen
5FU + Cisplatin 191 (96.5)
Others 7 (3.5)
Radiation dose (cGy, median [range]) 6300 (3060–7020)
Consolidation chemotherapy
No 58 (29.3)
Yes 140 (70.7)
CCRT complication*
No 132 (66.7)
Yes 66 (33.3)
ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; Gx, grade cannot
be assessed; CCRT, concurrent chemo- and radiotherapy.
*Esophagitis, general weakness, neutropenia, pneumonia, tracheo-esophageal fistula.
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CCRT and the impact of pre/post-CCRT sarcopenia on the
prognosis of these patients.
MATERIALS AND METHODS
Patients and Clinical Characteristics
All consecutive patients who were diagnosed with esophageal
cancer and treated with definite CCRT at Gangnam Severance
and Severance hospital fromAugust 2005 to December 2014 were
retrospectively collected for this analysis. A total of 287 patients
with pathologically proven esophageal cancer were included
after dedicated electronic medical records review. Of these, 9
patients had an additional surgery after CCRT, 25 patients had
overlapping of esophageal cancer with another cancer, and 55
patients did not have sufficient CT images to measure muscle
mass. Thus, except for these patients, a total of 198 patients were
finally included for our study.
The initial performance status of patients was recorded
by Eastern Cooperative Oncology Group (ECOG) score.
Hemoglobin, albumin and neutrophil/lymphocyte ratio (NLR)
at the time of diagnosis of esophageal cancer were collected to
identify patient’s nutritional and inflammatory status related to
prognosis (18). Tumor location, histopathologic grade, clinical
stage were classified according to AJCC/UICC staging (19).
Esophagogastroduodenoscopy, CT, endoscopic ultrasound, and
positron emission tomography-computed tomography (PET-
CT) were applied to determine the clinical stage. Patients were
observed at 3 to 6 months intervals until Aug 31, 2017 or death,
whichever came first. Overall survival (OS) was defined as the
length of time from the date of initial diagnosis to the date of
death. Progression free survival (PFS) was defined as the length of
time after treatment for a cancer ended that the patient survived
without any signs of symptoms of the cancer. The Institutional
Review Board of Gangnam Severance Hospital waived the need
for approval of this study.
Radiotherapy (RT) was performed with 3-dimentional
conformal RT or intensity-modulated RT (IMRT) starting on day
1 of chemotherapy and a conventional fractionation schedule
(1.8–2.0Gy per fraction, 5 days per week) and cone-down
technique were used in all patients. The gross tumor volume
(GTV) was delineated using (PEC/CT) fusion on the MIM
software (Cleveland, OH) or Pinnacle Radiotherapy Planning
System (Phillips Medical System, Andover, MA). Endoscopic
clips were also used for contouring GTV. The initial clinical
target volume (CTV) included the GTV plus a margin of at
least 5 cm longitudinally and 2 cm radially. The initial CTV
received 30.6–50.4Gy (median dose, 36Gy), and at the time
of cone-down, final CTV encompassed the GTV with a 2 cm
margin longitudinally and radially. The total prescribed radiation
dose ranged from 50.4 to 66Gy according to the physicians’
decisions. Previous study in our institution reported that higher
dose (>60Gy) yielded better outcome without increase of
any toxicity and higher dose scheme has been used in our
institution (20).
Two cycles of chemotherapy were administered during CCRT
period. Consolidation chemotherapy was conducted between
4 and 6 weeks after the completion of CCRT. Complications
associated with CCRT were defined as development of 1 or more
adverse effect with common toxicity criteria grade 2 or higher
during CCRT period.
Image Analysis
Because dual-energy X-ray absorptiometry (DXA) is used
infrequently in routine clinical practice, we used a previously
validated CT-based body composition method with scans
acquired at the initial diagnosis (e.g., whole-body PET-CT or
abdominal CT imaging). We also obtained post CCRT images
that were taken within 6months after the end of CCRT. The third
lumbar vertebra (L3) was selected as a landmark for calculation
since the cross-sectional area of tissues in this region provide an
established means of estimating body composition parameters
quantities in general population (21).
We obtained skeletal muscle volume and total adipose
tissue volume at L3 level, and divided by CT slice thickness,
respectively, to calculate skeletal muscle area and total adipose
tissue area. The MIM Vista software was used to demarcate
skeletal muscle, visceral fat tissue, and subcutaneous fat
tissue according to predefined validated boundaries based on
Hounsfield units (HUs). The following thresholds were applied:
−29 to +150 HU for skeletal muscle, −150 to −50 HU for
visceral fat tissue, and −190 to −30 HU for subcutaneous fat
tissue. The radiation oncologist and the radiotherapy technician
(Ik Jae Lee and Mi-jin Jeon) who performed these measurements
was blinded to the treatment outcomes of all patients to minimize
bias (Figure 1).
Skeletal muscle index (SMI), fat-free mass (FFM), and total
body fat mass (FM) were estimated as follows (21): SMI
(cm2/m2) = skeletal muscle area (cm2) / height2 (m2), FFM
(kg) = 0.3 ∗ skeletal muscle area (cm2) + 6.06, FM (kg) = 0.042
∗ total adipose tissue area (cm2) + 11.2. In general, sarcopenia
is defined as a L3 SMI of <55 cm2/m2 for men and <39
cm2/m2 for women, as proposed by international consensus of
TABLE 2 | Comparison of changes in body composition before and after CCRT.
Parameters Before CCRT After CCRT P-value
ALL
Body mass index (kg/m2) 22.6 (15.1–31.2) 21.5 (13.3–30.7) < 0.001
Skeletal muscle index (cm2/m2) 46.0 (27.2–67.7) 42.2 (20.0–81.4) < 0.001
Fat free mass (kg) 44.5 (29.1–63.2) 41.5 (21.3–75.8) < 0.001
Total body fat mass (kg) 18.9 (11.4–30.4) 18.2 (11.3–28.6) 0.207
MALE
Body mass index (kg/m2) 22.6 (15.1–31.2) 21.4 (13.3–30.7) < 0.001
Skeletal muscle index (cm2/m2) 46.3 (27.2–67.7) 42.6 (20.0–81.4) < 0.001
Fat free mass (kg) 44.9 (29.0–63.2) 41.6 (21.3–75.8) < 0.001
Total body fat mass (kg) 18.8 (11.4–30.4) 18.1 (11.3–28.6) 0.345
FEMALE
Body mass index (kg/m2) 23.5 (17.0–28.0) 22.6 (16.6–27.7) 0.123
Skeletal muscle index (cm2/m2) 38.4 (31.3–48.7) 33.8 (26.0–38.8) 0.012
Fat free mass (kg) 33.1 (30.2–38.1) 28.7 (25.0–32.8) 0.012
Total body fat mass (kg) 22.7 (14.2–26.3) 20.5 (14.4–26.1) 0.263
CCRT, concurrent chemo- and radiotherapy.
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cancer cachexia (22). However, we used Korean-specific cutoff
values of 49 cm2/m2 for men and 31 cm2/m2 for women
based on a previous epidemiologic study using DXA and a
regression equation,
L3muscle index of CT =
height − adjusted appendicular skeletal
muscle mass in DXA (kg/m2)− 1.17
0.11
to convert the CT value (9).
Statistical Analysis
All continuous variables were reported as median and range.
The chi-square and Fisher’s exact tests were used to compare
between various categorical variables, and Student t-test and
Mann-Whitney U-test were used for non-categorical variables.
Multivariate logistic regression analysis was used to identify
independent risk factors for predicting post–CCRT sarcopenia.
OS and PFS were estimated using the Kaplan-Meier method,
and differences between curves were evaluated using the log-
rank test. A Cox proportional hazards model was used to
analyze risk factors that affect OS. All variables with P < 0.05
was on the univariate analysis were entered the multivariate
analysis. The statistical calculations were performed using
SPSS version 18.0 for Windows software (SPSS Inc., Chicago,
IL, USA).
RESULTS
Baseline Characteristics of Patients and
Tumors
A total of 198 consecutive patients were enrolled in our study
(Table 1). The median age was 67 years (range 36–91), and
most of the patients were men (96%). One hundred ninety
patients (96%) had good ECOG performance score (0–1). Of
the 198 patients, 46 (23.2%) patients underwent esophageal stent
insertion due to obstructive symptoms. More than half (55.1%)
FIGURE 2 | Kaplan–Meier analysis of overall survival and progression free survival according to sarcopenia. (A) Overall survival according to pre–CCRT sarcopenia.
(B) Overall survival according to post–CCRT sarcopenia. (C) Progression free survival according to pre–CCRT sarcopenia. (D) Progression free survival according to
post–CCRT sarcopenia.
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TABLE 3 | Univariate and multivariate analysis of risk factors for overall survival.
Univariate analysis Multivariate analysis
HR (95% CI) P–value HR (95% CI) P–value
Age 0.994 (0.971–1.017) 0.598
Sex (male) 2.059 (0.507–8.369) 0.313
ECOG performance status (≥ 2) 5.195 (2.247–12.008) 0.001 3.805 (1.605–9.023) 0.002
NLR 1.065 (1.025–1.107) 0.001 1.059 (1.018–1.102) 0.005
Tumor location (middle & lower) 1.135 (0.719–1.793) 0.587
Tumor differentiation 1.076 (0.637–1.819) 0.784
cT stage (≥ cT3) 1.872 (1.197–2.927) 0.006 1.586 (1.004–2.504) 0.048
cN stage (≥ cN1) 1.842 (1.090–3.113) 0.023 1.354 (0.779–2.352) 0.283
Radiation dose (< 50Gy) 1.862 (0.861–4.029) 0.114
Consolidation therapy (no) 1.121 (0.714–1.760) 0.619
CCRT complication (yes) 1.216 (0.803–1.841) 0.355
Pre-CCRT BMI (< 23 kg/m2) 1.417 (0.944–2.126) 0.093
Post-CCRT BMI (< 23 kg/m2 ) 1.431 (0.910–2.251) 0.121
BMI decrement 1.058 (0.955–1.173) 0.278
Pre-CCRT sarcopenia 1.273 (0.837–1.937) 0.254
Post-CCRT sarcopenia 1.923 (1.183–3.127) 0.007 1.651 (1.007–2.704) 0.047
SMI decrement 1.049 (1.011–1.088) 0.011 1.042 (1.001–1.086) 0.046
HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; NLR, Neutrophil / lymphocyte ratio; cT, clinical tumor; cN, clinical nodal; CCRT, concurrent chemo- and radiotherapy;
BMI, body mass index; SMI, skeletal muscle index.
of the tumors were in the middle esophagus. The histologic type
of tumor was squamous cell carcinoma in most cases (98.5%)
and adenocarcinoma in 3 cases. Of all patients, 67.2% had a
clinical tumor stage greater than T2, and 74.2% had a clinical
nodal stage greater than N0. According to clinical TNM stage,
stage I was 30 patients (15.2%), stage II was 40 patients (20.2%),
stage III was 68 patients (34.3%), stage IVA was 37 patients
(18.7%), and stage IVB was 23 patients (11.6%). Median total
radiation dose was 6,300 cGy. There were 140 patients (70.7%)
who received the consolidation chemotherapy after CCRT. We
found 66 patients (33.3%) who suffered from CCRT related
complications. Among them, esophagitis was the most common
(n = 48). Other complications were general weakness (n = 9),
neutropenia (n= 6), pneumonia (n= 2), and tracheo-esophageal
fistula (n= 1).
Changes in Body Composition Before and
After Treatment
We compared BMI, SMI, FFM, and FM before and after CCRT
except 25 patients who did not have post–CCRT CT image.
BMI, SMI, and FFM after CCRT were statistically significantly
decreased (P < 0.001). Also, we identified 25 patients with
sarcopenia following CCRT. However, FM did not show any
significant difference before and after CCRT. In female subgroup,
there was no statistically difference in BMI before and after
CCRT (Table 2).
Analysis of Risk Factors Affecting Overall
Survival Rate
Patients with sarcopenia before CCRT did not showed
significantly decreased OS compared to non-sarcopenic
patients (Figure 2). However, patients with sarcopenia after
CCRT demonstrated significantly poor OS compared to
non-sarcopenic patients (median OS 45 months vs. 74
months, P = 0.007). Also, patient with sarcopenia after
CCRT showed poor PFS compared to non-sarcopenia
patients, but patients with sarcopenia before CCRT
did not.
We analyzed several risk factors that might influence OS
(Table 3). In univariate analysis, higher ECOG performance
status (≥2), higher NLR, clinical tumor stage (≥cT3), and
clinical nodal stage (≥cN1) showed significant relationship
with OS. The presence of sarcopenia before CCRT did
not affect OS. In contrast, patients who were diagnosed as
sarcopenia after CCRT showed impaired survival. Multivariate
analysis revealed that higher ECOG performance status,
higher NLR, higher clinical tumor stage, and post-CCRT
sarcopenia were independent risk factors for decreased OS.
Furthermore, SMI decrement was associated with poor OS
regardless of sarcopenia. On the other hand, tumor location,
tumor differentiation, radiation dose, consolidation therapy,
and CCRT complication did not show statistical correlation
with OS.
Also, we analyzed what factors affected post–CCRT
sarcopenia. The relationship between the factors described
in Table 1 and post–CCRT sarcopenia was analyzed.
As a result, male sex, CCRT complications, and tumor
differentiation (moderate and poorly differentiation)
showed statistically significant relationship in univariate
analysis. In multivariate analysis, male sex, and CCRT
complications were significantly associated with post–CCRT
sarcopenia (Table 4).
Frontiers in Oncology | www.frontiersin.org 5 May 2019 | Volume 9 | Article 366
Ma et al. Sarcopenia and Esophageal Cancer
TABLE 4 | Multivariate analysis of risk factor for post-CCRT sarcopenia.
Characteristics Odd ratio (95% CI) P-value
Sex (male) 11.967 (2.060–69.520) 0.006
CCRT complication* 2.741 (1.169–6.425) 0.020
Tumor differentiation (MD or PD) 2.625 (0.930–7.410) 0.068
CCRT, concurrent chemo- and radiotherapy; MD, moderate differentiation; PD,
poorly differentiation.
*Esophagitis, general weakness, neutropenia, pneumonia, tracheo-esophageal fistula.
Changes in Sarcopenic Status After CCRT
and Overall Survival
All study population were classified according to the timing of
onset of sarcopenia (Figure 3). They were divided 3 groups:
patients who were not diagnosed with sarcopenia after CCRT
(group A, n = 48, median follow up = 38 months), patients
who were not diagnosed with sarcopenia before CCRT, but
were diagnosed with sarcopenia after CCRT (group B, n = 25,
median follow up = 11 months), patients who were diagnosed
with sarcopenia before and after CCRT (group C, n = 101,
median follow up = 20 months). Patients who had never
been diagnosed with sarcopenia (group A) had a significantly
longer survival rate than group B and C (P = 0.016 and 0.024,
respectively). However, patients with post–CCRT sarcopenia had
no difference in survival rates regardless of pre–CCRT sarcopenia
(P= 0.454). In other words, patients with post–CCRT sarcopenia
showed worse overall survival than patients without post–CCRT
sarcopenia. Furthermore, the presence of pre–CCRT sarcopenia
did not affect the overall survival rate.
DISCUSSION
In this study, we investigated the relationship between the
sarcopenia and the prognosis of patients with esophageal cancer
who treated with definite CCRT. Although there have been
many similar studies, most of them have been related to surgery,
and studies in patients with CCRT have been lacking (14–17).
In addition, our study is characterized by comparing muscle
mass before and after treatment. As a result, the patient with
sarcopenia before CCRT did not show significant association
with overall survival, but the patient with sarcopenia after CCRT
did. In other words, presence of sarcopenia after CCRT affected
an unfavorable effect on the prognosis, regardless of whether it
occurred before or after treatment. Also, it was found that male
sex and CCRT related complications were associated with post
CCRT sarcopenia.
The relationship between sarcopenia and prognosis has
been known as controversial in patients with surgically treated
esophageal cancer. Sheetz et al. reported that core muscle size was
associated with poor OS, in patients following esophagectomy.
In contrast, it was not associated with OS, in patients receiving
neoadjuvant chemoradiation (6). Similar to this study, another
study found that the presence of sarcopenia did not show
significant correlation with a short- and long-term outcome in
esophageal cancer patients after neoadjuvant chemoradiotherapy
FIGURE 3 | Comparison of survival rates according to the time of onset of
sarcopenia. Group A: patients who were not diagnosed with sarcopenia after
CCRT (median survival = 73 months). Group B: patients who were not
diagnosed with sarcopenia before CCRT, but were diagnosed with sarcopenia
after CCRT (median survival = 17 months). Group C: patients who were
diagnosed with sarcopenia before and after CCRT (median survival = 28
months). Group A and B, P = 0.016; Group A and C, P = 0.024; Group B and
C, P = 0.454.
followed by esophagectomy (14). However, there were several
papers that proved the relationship between sarcopenia and
clinical outcome in patients after esophageal resection who
underwent neoadjuvant chemoradiotherapy (15–17). Our study
shows differences from previous studies in that only patients
who underwent definite CCRT were included. In addition, the
previous studies were mainly executed inWestern countries such
as Europe and the United States, but our study is characterized
by research conducted in Asia where esophageal squamous cell
carcinomas develop more often than adenocarcinoma.
Sarcopenia could be a characteristic of esophageal cancer
itself or one of the complications associated with treatment.
Cancer treatments such as surgery, chemotherapy, or RT are
known to contribute to muscle loss by causing anorexia. Also,
various circulating inflammatory mediators such as tumor
necrosis factor-α and interluekin-6 have been implicated in
excessive muscle proteolysis (23). In our study, we revealed
that patients with sarcopenia after CCRT were associated with
a poor prognosis. In contrast, the presence of sarcopenia
before treatment was not associated with prognosis. CCRT
complications were one of the factors when multivariate analysis
of factors related to the incidence of post-CCRT sarcopenia.
Although the cause of sarcopenia after CCRT is not yet
established, the characteristics of esophageal cancer itself, and
changes in nutritional status due to the complications of
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CCRT may contribute to sarcopenia. In our study, esophagitis
was the most common complication after CCRT. It could
cause dysphagia or odynophagia, and aggravate malnutrition
for patients (24). Not only topical anesthetics and analgesics,
but also dietary modification could be helpful to control the
symptoms (25). Preventing the occurrence of sarcopenia by
providing adequate nutritional support and proper management
for complications during the CCRT period could facilitate the
improvement of the patient’s prognosis.
Our study has several limitations. First, we collected data
retrospectively from electro medical records. It was not a
prospective study, and some data were limited. We could not
include 25 patients who did not undergo skeletal muscle mass
assessment after CCRT, and they should be considered in the
interpretation of data because the possibility of their poor
prognosis. Also, toxicity surveillance was performed imperfectly
due to retrospective design. Second, the definition of sarcopenia
was different from that of Western countries. International
consensus of cancer cachexia proposed the definition of
sarcopenia as a L3 muscle index of <55 cm2/m2 for men and
of <39 cm2/m2 for women (22). However, we did not use this
definition because the BMI of Western and Eastern people were
quite different. If western definitions are applied, the incidence
of pre-CCRT sarcopenia in our study rises from 62.6 to 84.8%.
We consider that the definition used inWestern countries are not
necessarily applicable to Korean esophageal cancer patients who
generally have a smaller physique.
In conclusion, we investigated the relationship between
prognosis and sarcopenia in esophageal cancer patients receiving
definite CCRT, and found that patients with sarcopenia identified
after CCRT were associated with a poor prognosis. That is to say,
post–CCRT sarcopenia can be a reliable predictor for prognosis.
This means that proper support for preventing skeletal muscle
loss during CCRT may help improve the prognosis of patients
with esophageal cancer. In particular, complications that occur
during CCRT may impair the nutritional status of the patient, so
it is important to cope with complications appropriately.
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